These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37507070)

  • 1. Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis.
    Liu MC; Bagnasco D; Matucci A; Pilette C; Price RG; Maxwell AC; Alfonso-Cristancho R; Jakes RW; Lee JK; Howarth P
    J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3650-3661.e3. PubMed ID: 37507070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.
    Kritikos V; Harvey ES; Stevens S; Katelaris CH; Langton D; Rimmer J; Farah CS; Gillman A; Hew M; Radhakrishna N; Thomas D; Gibson PG;
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):885-895.e13. PubMed ID: 36572182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma.
    Pilette C; Canonica GW; Chaudhuri R; Chupp G; Lee FE; Lee JK; Almonacid C; Welte T; Alfonso-Cristancho R; Jakes RW; Maxwell A; Price RG; Howarth P
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2646-2656. PubMed ID: 35753668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities.
    Casale T; Molfino NA; Silver J; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):354-362.e2. PubMed ID: 34038773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).
    Al-Lehebi RO; Al Ahmad M; Maturu VN; Mesa AG; Mahboub B; Garcia E; Fernandez P; Soares C; Abreu G; Dos Santos D; Queiroz J; Raimondi A; Laucho-Contreras M; Noibi S; Levy G; Bavbek S
    Adv Ther; 2024 Nov; 41(11):4008-4031. PubMed ID: 39215767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery.
    Silver J; Deb A; Laliberté F; Gao C; Bhattacharyya N
    Int Forum Allergy Rhinol; 2024 Jan; 14(1):5-17. PubMed ID: 37365852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
    Crimi C; Campisi R; Cacopardo G; Intravaia R; Nolasco S; Porto M; Pelaia C; Crimi N
    World Allergy Organ J; 2020 Sep; 13(9):100462. PubMed ID: 32994855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Gibson PG; Prazma CM; Chupp GL; Bradford ES; Forshag M; Mallett SA; Yancey SW; Smith SG; Bel EH
    Respir Res; 2021 Jun; 22(1):171. PubMed ID: 34098955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
    Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
    Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
    Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
    Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world unified airway benefits of mepolizumab: Effectiveness in patients with asthma and comorbid nasal polyps.
    Bernstein JA; Silver J; Packnett E; Lew CR; Robles Y; Deb A
    Ann Allergy Asthma Immunol; 2024 Oct; 133(4):422-429.e2. PubMed ID: 38972449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.
    Chupp G; Alobid I; Lugogo NL; Kariyawasam HH; Bourdin A; Chaker AM; Smith SG; Sousa AR; Mayer B; Chan RH; Matucci A
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3504-3512.e2. PubMed ID: 37586475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.
    Chen M; Choo E; Yoo B; Raut P; Haselkorn T; Pazwash H; Holweg CTJ; Hudes G
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):666-673. PubMed ID: 33465457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.
    Harrison T; Canonica GW; Chupp G; Lee J; Schleich F; Welte T; Valero A; Gemzoe K; Maxwell A; Joksaite S; Yang S; Howarth P; Van Dyke MK
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32817259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-5 therapies for asthma.
    Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.